| answer text |
<p>The Department regularly meets with colleagues in the National Institute for Health
and Care Excellence (NICE) to discuss a range of issues, including in relation to
the NICE’s methods for the evaluation of medicines. In 2022, the NICE introduced a
number of changes to make its methods and processes fairer, faster, and more consistent.
This includes the introduction of a broader severity modifier, in place of the end-of-life
modifier. Since the changes were introduced, 79% of the NICE’s appraisals of cancer
medicines carried out under the updated methods have recommended the use of the treatment
for some or all of the eligible patient population, either for routine use or use
through the Cancer Drugs Fund. The approval rate for all cancer appraisals carried
out since 2009, when the end-of-life modifier was introduced, is 78%.</p>
|
 |
